Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.13)
# 1,084
Out of 5,180 analysts
6
Total ratings
60%
Success rate
98.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.78 | +28.21% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $4 | $0.23 | +1,639.89% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $4.55 | +9.89% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $14.93 | +60.75% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $1.90 | +215.79% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.54 | +2,307.41% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.78
Upside: +28.21%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $4
Current: $0.23
Upside: +1,639.89%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $4.55
Upside: +9.89%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $14.93
Upside: +60.75%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.90
Upside: +215.79%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.54
Upside: +2,307.41%